Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Carrie McAdam-Marx
SGLT2 Inhibitors or GLP-1 Receptor Agonists as Second-Line Therapy in Type 2 Diabetes: Patient Selection and Perspectives
Vascular Health and Risk Management
Related publications
Combining SGLT2 Inhibitor and GLP-1 Agonist: Exaggerated Weight Loss in a Morbidly Obese Patient With Type 2 Diabetes
British Journal of Diabetes
Pdb68 - Cost-Effectiveness Analysis of Exenatide Versus GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
SGLT2 Inhibitor and GLP-1 Receptor Agonist Combination Therapy Substantially Improved the Renal Function in a Patient With Type 2 Diabetes: Implications for Additive Renoprotective Effects of the Two Drug Classes
Internal Medicine
Internal Medicine
Medicine
Role and Development of GLP-1 Receptor Agonists in the Management of Diabetes
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal Medicine
Pharmacology
Combination Therapy With Once-Weekly Glucagon Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes: A Case Series
Pharmacy Practice
Pharmaceutical Science
Pharmacy
Evaluating Preferences for Profiles of GLP-1 Receptor Agonists Among Injection-Naïve Type 2 Diabetes Patients in the UK
Patient Preference and Adherence
Pharmacology
Health Policy
Medicine
Toxicology
Social Sciences
Pharmaceutics
Adherence to GLP-1 Receptor Agonist Therapy Administered by Once-Daily or Once-Weekly Injection in Patients With Type 2 Diabetes in Germany
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal Medicine
Pharmacology
Correction To: Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults With Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine
Advances in Therapy
Medicine
Pharmacology
Pdb112 - Treatment and Dosing Patterns Among Patients With Type 2 Diabetes (T2d) Initiating Glucagon-Like Peptide-1 Receptor Agonists (Glp-1 Ras) in Several Countries
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental